retatrutide mechanism triple agonist gip glp-1 glucagon Retatrutide: How the Compares to Tirzepatide Structural insights into the triple
Description
2022 Feb 25;32:121-129
The effects became measurable after 20 weeks of treatment, providing objective biochemical confirmation of what patients reported experiencing
The mean LVEF was 33.7% and 35.4% in the liraglutide and placebo groups, respectively, and 60% of patients had ischaemic heart disease
For participants receiving 40 mg daily of oral semaglutide, three different dose-titration protocols were used where patients were titrated up to the full 40 mg dose in 6 weeks (fast dose escalation), 12 weeks (standard dose escalation), or 24 weeks (slow dose escalation)
